Company Interview / From scans to solutions: Inside Aptium AI's global ambitions

Artificial intelligence may dominate headlines, but its most immediate impact is increasingly physical. Australian medtech company Aptium AI is a case in point, combining 4D scanning, multispectral imaging and AI to deliver near-instant, high-resolution 3D models for clinical use.

The company’s handheld device captures multiple images in a fraction of a second, stitching them into a precise 3D model that can be used by clinicians to design customised treatments. Aptium AI is initially targeting podiatry, which CEO Carl Stubbings says is a strategic entry point driven by both accessibility and urgent clinical need.

Globally, around 500 million people live with diabetes, a figure expected to rise sharply by 2030. More than a third will develop foot ulcers, a leading cause of lower limb amputations. Aptium AI’s technology aims to intervene early, identifying pressure points and enabling tailored orthotics that reduce the risk of ulcer formation.

Beyond podiatry, Executive Chair Dr Mel Bridges sees significant opportunity across broader healthcare, including surgical planning, as well as industrial applications such as safety monitoring in mining.

Commercially, Aptium AI is pursuing a dual revenue model: upfront hardware sales paired with recurring “pay-per-scan” software income. Early demand is emerging across Europe, the Middle East and India, with further expansion planned into Asia and the Americas.

Currently raising $5 million, the company is focused on scaling manufacturing and building its install base. If successful, management expects to achieve revenue generation within months and profitability within a year of launch, positioning Aptium AI as a potential global leader in advanced imaging technology.